B Cell Lymphoma
From the Journals
Adding polatuzumab extends survival in relapsed/refractory DLBCL
The combination offers a viable alternative for a group of patients with historically “dismal” outcomes, investigators said.
News from the FDA/CDC
FDA approves Brukinsa for relapsed, refractory MCL
The Bruton tyrosine kinase (BTK) inhibitor zanubrutinib showed high overall response rates in two clinical trials.
From the Journals
Gene signature may help guide initial CLL treatment choice
A 17-gene expression signature may help predict which patients with IGHV-unmutated disease will benefit from frontline FCR chemoimmunotherapy or...
Conference Coverage
Armored CAR T cells elicit responses in NHL patients
NATIONAL HARBOR, MD. – ICTCAR014, a dominant negative PD-1 armored CAR T-cell therapy, produced responses in 12 of 13 non-Hodgkin lymphoma...
Conference Coverage
Consider renal function in TLS risk assessment of venetoclax-treated CLL
EDINBURGH – Impaired renal function may indicate excess risk of tumor lysis syndrome (TLS) in venetoclax-treated...
From the Journals
Pembrolizumab shows promise for relapsed/refractory PMBCL
The findings raise the question of whether PD-1 blockade could resensitize tumors to chemotherapy.
Perspectives
Primary CNS lymphoma: R-CHOP hits back
Twenty years after it was concluded that there was no role for R-CHOP in the treatment of primary CNS lymphoma, researchers are reconsidering that...
Conference Coverage
PJP prophylaxis may be unnecessary for CLL patients on BTK inhibitors
EDINBURGH – The findings show an overall low pneumocystis jiroveci pneumonia prevalence in patients not receiving prophylaxis.
From the Journals
Ibrutinib linked to hypertension in B-cell malignancies
New or worsening hypertension was also linked with a greater risk of major adverse cardiac events.
From the Journals
Best treatment approach for early stage follicular lymphoma is unclear
Overall survival rates were similar with different treatment approaches, including watchful waiting.
From the Journals
Follow-up shows favorable results with acalabrutinib in MCL
The median duration of response exceeded 2 years with acalabrutinib monotherapy.